Hepatoprotective Effects of Nonpolar Extracts from Inflorescences of Thistles *Cirsium vulgare* and *Cirsium ehrenbergii* on Acute Liver Damage in Rat

Eduardo Fernández-Martínez, Maribel Jiménez-Santana, Mónica Centeno-Álvarez, Jose Martín Torres-Valencia, Mineko Shibayama, Raquel Cariño-Cortés

Center for Research on Reproductive Biology, Medicine Department, Institute of Health Sciences, Autonomous University of Hidalgo's State, 1Department of Basic Sciences and Engineering, Autonomous University of Hidalgo's State, 2Center for Research on Applied Science and Advanced Technology of National Polytechnic Institute, 3Department of Infectomics and Molecular Pathogenesis, Center for Research and for Advanced Studies of IPN, Mexico City, Mexico

Submitted: 22-06-2017 Revised: 29-08-2017 Published: 31-01-2018

**ABSTRACT**

**Background:** Drugs for the treatment of liver diseases are scarce and not effective enough. Some species of the genus *Cirsium* possess hepatoprotective activity. There are no studies on the hepatoprotective effects of nonpolar extracts from inflorescences of thistles *Cirsium vulgare* and *Cirsium ehrenbergii*, and there are few reports on their chemical composition. **Objective:** The aim is to obtain the hexane extract from inflorescences of both thistles and to identify preliminarily their main chemical component, and to evaluate the hepatoprotective properties of the extracts. **Materials and Methods:** Hexane extracts were obtained using a Soxhlet apparatus. The chemical composition was analyzed using infrared spectroscopy and gas chromatography-mass spectrometry. Two doses (250 and 500 mg/kg, p.o.) of both extracts were administered to assess their hepatoprotective effect on acute carbon tetrachloride (TC)-induced liver damage in rats using biochemical markers of necrosis, cholestasis, functionality, oxidative stress, and histological analysis. **Results:** Extracts were shown to have a very similar chemical profile. Their major constituent seems to be lupeol acetate. The two doses of both extracts demonstrated comparable hepatoprotective properties because they significantly diminished all the liver injury indicators (*P* < 0.05) and were corroborated using histopathology. **Conclusion:** This is the first study on the hepatoprotective effects of nonpolar extracts from inflorescences of thistles *C. vulgar* and *C. ehrenbergii*. Hexane extracts administration totally prevented the acute TC-induced liver damage. The preliminary chemical analysis strongly suggests the lupeol acetate as their major constituent. Lupeol and its derivatives have been previously reported as antiinflammatory and hepatoprotective agents. **Key words:** *Cirsium ehrenbergii*, *Cirsium vulgare*, hepatoprotective, liver damage, lupeol acetate

**SUMMARY**

- Hexane extracts of both thistles kept normal liver functionality and glycogen store in carbon tetrachloride-induced acute liver damage.
- Hexane extracts of both thistles showed anti-necrotic and anti-cholestatic effects, also diminished the lipid peroxidation and nitric oxide levels on the carbon tetrachloride-induced acute liver damage.
- The two doses of hexane extracts administered (250 and 500 mg/kg) prevented the liver injury in a very similar extent.
- Both nonpolar extracts are chemically very similar and their main compound seems to be lupeol acetate.

**INTRODUCTION**

Liver diseases are one of the leading causes of death; they are caused by viral infections, chronic alcoholism, nonalcoholic fatty liver disease, and autoimmune illnesses, which may chronically be precursors of cirrhosis. Cirrhosis is the late-stage liver disease, which can proceed to hepatocellular carcinoma. Pharmacological treatment options for liver diseases and cirrhosis are limited, expensive, and not quite effective. The use of medicinal herbs and plant-derived compounds is growing worldwide.
Herbal medicines for liver diseases therapy require pharmacological valuation of their efficacy as novel hepatoprotective phytodrugs. Genus *Cirsium* Mill. (Asteraceae or Compositae) comprises of flowering plants commonly known as thistles, which are despised just as weedy invasive herbs. Genus *Cirsium* is widely distributed and original from Europe, Asia, and Africa, also it was introduced in America and Australia. Diverse pharmacological effects have been described for species of *Cirsium*, anti-microbial, anti-cancer, anti-oxidant, anti-diabetic, hypolipidemic, pro-cognitive, neuroprotective, analgesic, and anti-inflammatory activities. There are reports about the hepatoprotective effects of some species of *Cirsium* from Asia evaluated *in vitro* and *in vivo* as well as of their isolated major constituents. Nevertheless, only polar extracts (water, methanol, and ethanol as solvents) from the thistles were used in all these studies to obtain polar compounds, such as flavonoids, which are very well-known as anti-oxidant and anti-inflammatory agents, like those of silymarin from *Silybum marianum* that has proven effects on chronic liver diseases. Thus, to assess the hepatoprotective activity of nonpolar extracts from thistles should be of interest because some authors have pointed out that the bioactive molecules remain in nonpolar extracts rather than in the polar ones from *Cirsium*. In addition, there are no studies on the hepatoprotective effects of *Cirsium vulgare* (Savi) Ten. and *C. ehrenbergii* Sch. Bip., besides there are few reports on their chemical composition. Inflorescences and leaves of *C. vulgare* are used in Polish folk medicine as diuretic, astringent, anti-inflammatory, and anxiolytic agents. Inflorescences and roots of *C. ehrenbergii* are used in Mexico for the treatment of gastritis, diabetes, hemorrhoids, cough, and vaginal bleeding. Therefore, the aim of this study was to obtain the hexane extracts from inflorescences of both thistles, to identify preliminarily their main chemical component, and to evaluate the hepatoprotective properties of these extracts.

**MATERIALS AND METHODS**

**Chemicals**

All reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA). Solvents and the carbon tetrachloride (CCl₄, TC) were analytical grade and purchased from J.T. Baker (Phillipsburg, NJ, USA).

**Plant materials and preparation of nonpolar extracts**

*C. vulgare* inflorescences were collected from municipality of “Mineral de la Reforma” (20° 09’ 00” N latitude; 98° 26’ 00” W longitude) and *C. ehrenbergii* inflorescences were collected from municipality of “Mineral del Chico” (20° 12’ 11” N latitude; 98° 44’ 52” W longitude), in Hidalgo’s State, Mexico, during the summer season. The identity of the plants was taxonomically confirmed and voucher specimens (15598IMSSM and 15597IMSSM, respectively) were deposited at the “Herbario del Centro Médico Siglo XXI” of the “Instituto Mexicano del Seguro Social”, Mexico. Inflorescences were dried and milled. Hexane extracts were carried out by exhaustive extraction in a Soxhlet apparatus. The solvent was removed by total evaporation in vacuum at 40°C, and the extracts were obtained as dark green honeys with characteristic odors. The extraction yield was 2.05% and 7.19% for *C. vulgare* and *C. ehrenbergii*, correspondingly.

**Preliminary chemical analysis of the nonpolar extracts by infrared spectra and gas chromatography-mass spectrometry**

To compare the nonpolar compounds, present in both hexane extracts, an initial characterization of their functional groups was performed using Fourier transform infrared spectra (FT-IR, Perkin-Elmer Spectrum version 10.4.00, Norwalk, CT, USA). The characterization was carried out by recording the transmittance (%) of the extracts in the frequency range of 4000 cm⁻¹-400 cm⁻¹. The samples were pelletized with KBr for the infrared (IR) spectroscopy.

Gas chromatography-mass spectrometry (GC-MS) analyses of the hexane extract samples were performed using an AutoSystem XL-GC equipped with an ENS5M column (30 m × 0.25 mm ID × 0.25 μm film thickness) and coupled to a selective quadrupole TurboMass-MS detector with an electron impact (EI) ionization system at 70 eV (Perkin-Elmer, Norwalk, CT, USA). The diluted extract samples were manually injected (1.0 μL) and transferred in splitless mode. The flow rate of helium as the carrier was 1.0 mL/min at 8 psi. The oven temperature started at 60°C and was gradually increased up to 330°C at a rate of 8°C/min, where it was maintained for 30 min. The mass spectra were set and recorded in scan mode from 15 to 600 m/z.

The preliminary identification of only the major detected compound (maximum peak height for that compound, %) from each hexane extract gas chromatogram was accomplished by comparing its retention time and mass spectra with those available from the computerized spectral database of National Institute of Standard and Technology (NIST MS Search 1.7, Gaithersburg, MD, USA) and from published literature.

**Animals**

Male Wistar rats weighing approximately 200–250 g were housed in standard plastic cages at a temperature of 22°C–24°C, under a 12 h light–dark cycle. They had free access to food (standard Purina chow diet, USA) and purified water. All the animals received humane care according to the Institution’s guidelines, the Mexican Official Norm (NOM-062-ZOO-999) for the production, care and use of laboratory animals, and the criteria outlined in the Guide for the Care and Use of Laboratory Animals (National Institutes of Health 1985).

**Acute tetrachloride-induced liver damage *in vivo*: Experimental groups, treatment, and doses**

Rats were divided into eight groups (n = 7). The first group was the normal control group (vehicle for extracts + vehicle for TC [VE + VTC]) that received three p.o. doses (12 h in between each dose) of 1 mL of olive oil as the VE; 2 h after the second administration of VE, the rats were orally given 1 mL of mineral oil as the vehicle for TC (VTC). Remaining groups underwent the same administration schedule. The second (Ecv500 + VTC) and third (Ece500 + VTC) groups received a dose of 500 mg/kg of the *C. vulgare* and *C. ehrenbergii* extracts, respectively, thrice orally dissolved in their vehicle and received the VTC p.o. too; both were control groups intended to show any adverse effect of the thistles per SE on normal rats. The fourth group was the damaged control (VE + TC), wherein rats received the VE thrice orally, and a single dose of 4 g/kg TC dissolved in its vehicle (1:1, v/v). The fifth (Ecv250 + TC) and sixth (Ece500 + TC) groups were administered with their respective doses of 250 and 500 mg/kg of *C. vulgare* extract and were injured by TC. Finally, seventh (Ece250 + TC) and eighth (Ece500 + TC) groups were administered their respective doses of 250 and 500 mg/kg of *C. ehrenbergii* extract and were damaged by TC.

The two assayed extract doses are considered to be middle doses and are based on previous reports wherein the hepatoprotective effects of *Cirsium* species were assessed in rats and mice. Animals were sacrificed by exsanguination under light ether anesthesia 24 h after TC administration; blood sample was collected by cardiac puncture using a syringe containing sodium heparin as an anticoagulant. The liver was rapidly removed and rinsed in saline. Samples were either kept on ice for immediate use or frozen at −70°C until analyzed.
Plasma enzyme activities and bilirubin determinations

Plasma was obtained for the determination of the canalicular membrane enzyme activities of cholestasis markers, such as alkaline phosphatase (AP) and γ-glutamyl transpeptidase (GGTP), and for the cytosolic activity of the necrosis indicator alanine aminotransferase (ALT) as well as for the quantification of the cholestasis and liver functionality marker direct (DB) and total (TB) bilirubin concentration (TECO Diagnostics kit, CA, USA). [46, 47]

Glycogen determination

Small liver pieces (0.5 g) were separated for glycogen measurement using anthrone-sulfuric acid reagent. [46]

Assessment of lipid peroxidation

The extent of lipid peroxidation (LP) was estimated in liver homogenates by measuring malondialdehyde (MDA) formation using the thiobarbituric acid method. [48] Protein was determined according to Bradford using bovine serum albumin as a standard. [49]

Hepatic nitric oxide determination

Hepatic nitric oxide (NO) amounts were determined from liver extracts obtained as previously reported [48] using a commercial nitrate/nitrite enzyme colorimetric assay kit (Cayman Chemical Co., MI, USA). Hepatic NO amounts are expressed as nitrite and nitrate (NO^2^- + NO^-^3) nmol/g of wet tissue.

Histology

Liver samples were taken and fixed with 10% formaldehyde in phosphate-buffered-saline for 24 h. They were washed with tap water, dehydrated in alcohols and embedded in paraffin. Sections of 6–7 μm were mounted on glass slides covered with silane, previous elimination of paraffin, and were used for hematoxylin/eosin staining for histological examinations using light microscopy. [49]

Statistical analysis

An ANOVA with the Student–Newman–Keuls test was used to compare groups. The resulting data are expressed as the means ± standard error of the mean and were analyzed using Sigma Stat software version 3.1 (Systat Software Inc., San Jose, CA, USA). The difference was considered statistically significant when P < 0.05.

RESULTS

Hexane extracts of both thistles are very similar and share the same major constituent

The initial characterization of the nonpolar major secondary metabolite present in the hexane extracts of the thistles was achieved by FT-IR spectra [Figure 1a]. The spectra of C. vulgare and C. ehrenbergii were overlaid and show very similar patterns of characteristic absorption bands of functional groups assigned as follows, IR ν^max^ (KBr): 2923 and 2853 (C-H, alkane), 1729 (C = O, ester carbonyl), 1462 and 1378 (-CH(CH3)2 dimethyl groups), 1245 (C-O, ester), 1168, 1097, 1025, 980 and 881 (-CH = CH2), 707 cm^-1. GC chromatograms of the hexane extracts evidenced that they share at least eight compounds proportionally in a similar abundance; however, the same major constituent (highest peak) was present in both extracts at the average retention time of 40.19 min [Figure 1b]. Just the fragmentation pattern of the main compound from C. ehrenbergii is presented [Figure 1c], EI-MS (m/z): 249, 207, 203, 190, 189 (90%), 175, 147, 121 (57%), 109 (60%), 95 (65%), 81 (57%), 69, 55 (50%), 43 (100%), and 41, 28. That fragmentation pattern was compared using the NIST database which found a high match with the lupeol acetate fragmentation pattern.

Effect of nonpolar extracts from Cirsium vulgare and Cirsium ehrenbergii on acute tetrachloride-induced liver damage in vivo

Figure 2 depicts the plasma enzyme activities of AP and GGTP as well as DB and TB concentrations. Due to TC-provoked injury, the AP activity [Figure 2a] was increased almost two-fold in the damaged group (VE + TC) when compared with the normal control group (VE + VTC). Administration of the hexane extracts did not elevate that marker per se even using 500 mg/kg. However, the treatment with the two doses of both thistles decreased the enzyme activity during the liver injury compared with VE + CT, although only the doses of C. ehrenbergii diminished it significantly (P < 0.05) in a dose-dependent manner, which shows an anticholestatic effect.

GGTP enzyme activity [Figure 2b] was increased 5-fold by TC administration (P < 0.05) with respect to that in VE + VTC control
Figure 2: Plasma cholestasis markers: (a) AP and (b) GGTP activities; (c) DB and (d) TB concentrations from rats treated with vehicles, TC, extracts (250 and 500 mg/kg) or combined. (a) Different versus VE + VTC, (b) different versus VE + TC, P < 0.05. AP: Alkaline phosphatase; GGTP: γ-glutamyl transpeptidase; DB: Direct bilirubin; TB: Total bilirubin; TC: Tetrachloride; VE: Vehicle for extract; VTC: vehicle for tetrachloride

Pharmacognosy Magazine, Volume 13, Issue 52, October-December 2017 (Supplement 4)
aliphatic aldehydes\(^{[12,39]}\) in fact, most of them have been described in hexane extracts from other Cirsium species.\(^{[55-57]}\) However, the precise constituents of C. ehrenbergii inflorescences have not yet been reported.\(^{[37]}\) In this study, the preliminary chemical analysis on both hexane extracts strongly suggested lupeol acetate as the major constituent. Indeed, lupeol acetate, lupeol, and lupenone have been found in C. setosum and C. japonicum.\(^{[31,58]}\) Besides, the IR spectra and the pattern of fragmentation of GC-MS of this study are in agreement with several reported spectral analyses of lupeol acetate.\(^{[59-62]}\) Furthermore, this family of lupeol derivatives have recognized hepatoprotective activity in diverse models.
of liver damage. Lupeol acetate has been reported to diminish the TC-induced liver injury markers, ALT, LP as MDA, NO, and reduced the pro-inflammatory cytokine tumor necrosis factor-α (TNF-α). Cholestasis is the mechanical or functional stoppage of bile flow in the intrahepatic or extrahepatic bile ducts, with bile components passing into the blood. The cholestasis indicators AP and GGTP were increased by TC as well as the necrosis marker ALT. TC elevated plasma DB and TB as sign of impaired excretory hepatic functions by cholestasis. However, the administration of the extracts showed anti-cholestatic and anti-necrotic effects on all the biochemical markers. Although ALT activity was significantly increased by high dose of extracts, such dose-dependent elevation was neither synergized with TC administration nor replicated in other liver damage indicator; perhaps, some metabolites augment its enzyme activity per se. These results are in agreement with various reports wherein the administration of diverse Cirsium extracts prevented the elevation of ALT and AP in liver damage models, although polar extracts rich in flavonoids were used in those studies. Constituents of the hexane extracts may have similar chologogue effects, perhaps through activating canalicular membrane transporters or by inducing the bilirubin conjugation to improve the excretion of bile products. Anti-cholestatic and anti-necrotic properties may also be related to the immunomodulatory effects of lupeol derivatives.

Hepatic glycogen is the main source of energy in the body and is indicative of metabolism and functionality, NO is either a mediator of liver injury or a protective mechanism and is induced by pro-inflammatory cytokines such as TNF-α. Glycogen synthesis and glycogenolysis are affected by TNF-α and NO; therefore, this marker is very sensitive to liver stress. The treatment with thistle extracts completely prevented the TC-induced depletion of glycogen, possibly because hepatic NO was inhibited too. These activities may be due to the lupeol acetate content; besides, some lupeol derivatives have activities as NO and pro-inflammatory cytokine targets and future prospects. Int J Mol Sci 2015; 16:28705-45. Several hepatotoxic chemicals cause liver damage through free radicals that provoke oxidative stress. Hexane extracts prevented the TC-induced LP; this anti-oxidant effect may be also associated with the lupeol derivatives content. These results suggest that despite the nonpolar constituents of hexane extracts are not free radical scavengers, as flavonoids of Cirsium polar extracts, a different anti-oxidant pathway may be implicated at nuclear receptor level due to the biological activities of sterols and lipids from nonpolar extracts. The hepatoprotective properties demonstrated by the biochemical markers for the thistle extracts were corroborated through histopathological analysis, wherein hepatic parenchymal damage was prevented.

CONCLUSION

This is the first study on the hepatoprotective effects of nonpolar extracts from inflorescences of thistles C. vulgare and C. ehrenbergii. The preliminary chemical analysis strongly suggests the lupeol acetate as their major constituent. The hexane extracts of these thistles deserve further chemical and pharmacological studies as hepatoprotective agents.

Acknowledgements

The authors would like to thank BióI. José Ayala Dávila for bibliographic search as well as M. C. E. Luis Carlos Romero-Quezada for administrative support. This work was supported by the grants “FOMIX-Hidalgo-CONACyT, key project HGO-2008-C01-97092, and PAI-UAEH, key project DI-ICSA-MED-SF-046, number 3262,” Mexico.

Financial support and sponsorship

Grants “FOMIX-Hidalgo-CONACyT, key project HGO-2008-C01-97092, and PAI-UAEH, key project DI-ICSA-MED-SF-046, number 3262.”

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Byass P. The global burden of liver disease: A challenge for methods and for public health. BMC Med 2014;12:159.
2. Mokdad AA, Lopez AD, Shariant S, Lozano R, Mokdad AH, Stanaway J, et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: A systematic analysis. BMC Med 2014;12:145.
3. Muriel P, Rivera-Espinosa Y. Beneficial drugs for liver diseases. J Appl Toxicol 2008;28:93-103.
4. Filizof C, Goldstein BJ, Williams RN, Sanjay A. Non-alcoholic steatohepatitis: Limited available treatment options but promising drugs in development and recent progress towards a regulatory approval pathway. Drugs 2015;75:1373-92.
5. Saikani A, Kutty SK. Plant-derived compounds in clinical trials. Drug Discov Today 2008;13:161-71.
6. Inamdar N, Edalat S, Kotwal VB, Pawar S. Herbal drugs in milieu of modern drugs. Int J Green Pharm 2008;2:2-8.
7. Hong M, Li S, Tan HY, Wang N, Tsao SW, Feng Y, et al. Current status of herbal medicines in chronic liver disease therapy. The biological effects, molecular targets and future prospects. Int J Mol Sci 2015; 16:28705-45.
8. Tan HY, San-Marina S, Wang N, Hong M, Li S, Li L, et al. Preclinical models for investigation of herbal medicines in liver diseases: Update and perspective. Evid Based Complement Alternat Med 2016;2016:4750163.
9. Krestov PV. Forest Vegetation of Easternmost Russia (Russian Far East). In: Kolbek J, Sludek M, Box ED, editors. Forest Vegetation of Northeast Asia (Geobotany). 1st ed. Amsterdam, Netherlands: Springer; 2003. p. 93-180.
10. Klinkhammer PG, De Jong TJ. Biological flora of the British Isles: Cirsium vulgare (Savi) Ten. (Carduus lanceolatus L., Cirsium, lanceolatum (L.) Scop., non Hill). J Ecol 1993;81:177-91.
11. Slotta TA, Horvath DP, Foley ME. Phylogeny of Cirsium spp. in North America: Host specificity does not follow phylogeny. Plants (Basel) 2012;1:61-73.
12. Jordan-Thaden IE, Louda S. Chemistry of Cardus and Cirsium: A role in ecological risk assessment for biological control of weeds? Biochem Syst Ecol 2003;31:1353-96.
13. San Martin JA. Medicinal plants in central Chile. Econ Bot 1983;37:216-27. Available from: http://www.lingk.springer.com/10.1007/BF02895788. [Last accessed on 2017 Mar 22].
14. Oonbey GB. Cytotaxonomic notes on eleven species of Cirsium from eastern China. Brittonia 1968;20:336-42. Available from: http://www.lingk.springer.com/10.2307/2805691. [Last accessed on 2017 Mar 22].
15. Nazaruk J, Czechowska SK, Markiewicz R, Borawska MH. Polyphenolic compounds and in vitro antimicrobial and antioxidant activity of aqueous extracts from leaves of some Cirsium species. Nat Prod Res 2008;22:1583-8.
16. Borawska MH, Czechowska SK, Markiewicz R, Socha K, Nazaruk J, Palka J, et al. Enhancement of antibacterial effects of extracts from Cirsium species using sodium picolinate and estimation of their toxicity. Nat Prod Res 2010;24:554-61.
17. Loizzo MR, Statti GA, Tundis R, Conforti F, Andri S, Menichini F, et al. Antimicrobial activity and cytotoxicity of Cirsium tenoreanum. Fitoterapia 2004;75:577-80.
18. Ozcelik B, Orhan DD, Karaoglu T, Ergun F. Antimicrobial activities of various Cirsium hypoleucom extracts. Ann Microbiol 2005;55:135-8.
19. Liu S, Luo X, Li D, Zhang J, Qiu D, Liu W, et al. Tumor inhibition and improved immunity in mice treated with flavone from Cirsium japonicum DC. Int Immunopharmacol 2006;6:1387-90. Available from: http://www.lingkhub.elsevier.com/retrieve/pii/S1567576906000610. [Last accessed on 2017 Mar 22].
20. Yin Y, Heo SI, Wang MH. Antioxidant and anticancer activities of methanol and water extracts from leaves of Cirsium japonicum. Appl Bioi Chem 2008;51:160-4. Available from: http://www.koreascience.or.kr/journal/view.jsp?ji=E1008F&py=2008 and vnc=v51n4&sp=160. [Last accessed on 2017 Mar 22].
21. Yin J, Heo SI, Wang MH. Antioxidant and antidiabetic activities of extracts from Cirsium japonicum roots. Nutr Res Pract 2008;2:247-51.
22. Jung HA, Kim YS, Choe JS. Quantitative HPLC analysis of two key flavonoids and inhibitory

EDUARDO FERNÁNDEZ-MARTÍNEZ, et al.: Hepatoprotection by Nonpolar Thistle Extracts

Pharmacognosy Magazine, Volume 13, Issue 52, October-December 2017 (Supplement 4)
activities against aldose reductase from different parts of the Korean thistle, Cirsium maackii. Food Chem Toxicol 2009;47:2790-7.

23. Kwon HY, Ryu MR, Lee YJ. The effects of Cirsium japonicum on lipid profile in ovarioctomized rats. Biomol Ther 2008;16:293-8.

24. Liao Z, Chen X, Wu M. Anti-diabetic effect of flavones from Cirsium japonicum in diabetic rats. Arch Pharm Res 2010;33:353-62.

25. Waleśniak A, Nazaraj J, Braszko JJ. Pro-cognitive effects of Cirsium rivulare extracts in rats. J Ethnopharmacol 2010;129:261-7.

26. Chung MJ, Lee S, Park YI, Lee J, Kwon KH. Neuroprotective effects of phytosterols and flavonoids from Cirsium setosum and Aster Scaber in human brain neuroblastoma SK-N-SH cells. Life Sci 2016;148:173-82.

27. Martinez-Vázquez M, Ramírez Aparo TD, Lastra AL, Bye R. A comparative study of the analgesic and anti-inflammatory activities of pectolinarin isolated from Cirsium subconicaeum and linarin isolated from Buddleia davidii. Planta Med 1998;64:134-7.

28. Jung HA, Jin SE, Min BS, Kim BW, Choi JS. Anti-inflammatory activity of Korean thistle Cirsium maackii and its major flavonoid, luteolin 5-O-glucoside. Food Chem Toxicol 2012;50:2171-9.

29. Ku KL, Tsai CT, Chang WM, Shen ML, Wu CT, Liao HF, et al. Hepatoprotective effect of Cirsium arisarum and Kitamura in tacrine-treated hepatopa hep 3B cells and C57BL mice. Am J Chin Med 2008;36:355-68.

30. Lee SH, Heo SI, Li L, Lee MJ, Wang MH. Antioxidant and hepatoprotective activities of Cirsium setosum Nakai against CCl4-induced liver damage. Am J Chin Med 2008;36:107-14.

31. Choi YJ, Yoon Y, Choi HS, Park S, Oh S, Jeong SM, et al. Effects of medicinal herb extracts and their components on steatogenic hepatotoxicity in sk-hep1 cells. Toxicol Res 2011;27:211-6.

32. Wan Y, Liu LY, Hong ZF, Peng J. Ethanol extract of Cirsium japonicum attenuates hepatic lipid accumulation via AMPK activation in human hepG2 cells. Exp Ther Med 2014;8:79-84.

33. Yoo YM, Nam JH, Kim MY, Choi J, Park JH. Pectolinarin and pectolinarigenin of Cirsium setosum prevent the hepatic injury in rats caused by D-galactosamine via an antioxidant mechanism. Biol Pharm Bull 2008;31:760-4.

34. Park JC, Hurr JM, Park JK, Kim SC, Park JR, Choi SH, et al. Effects of methanol extract of Cirsium japonicum var. Usunriense and its principle, hespinulin-D-O-hepesperidinose on hepatic alcohol metabolizing enzymes and lipid peroxidation in ethanol-treated rats. Phytother Res 2004;18:19-24.

35. Federico A, Dallio M, Loguercio C. Silvermary/Silvyn and chronic liver disease: A Marriage of many years. Molecules 2017;22: pii: E191.

36. Lee WB, Kwon HC, Cho OR, Lee KC, Choi SU, Baek NI, et al. Phytochemical constituents of Cirsium setosum Nakai and its cytotoxicity against human cancer cell lines. Arch Pharm Res 2002;25:628-35.

37. Fernández-Martínez E, Diaz-Espinoza R, Villavicencio-Nieto MA, Pérez-Escandón BE, Pérez-Hernández N, Macías A, et al. Preliminary phytochemical and biological study of Cirsium erbenhengi. Proc West Pharmacol Soc 2007;50:162-4.

38. Perez Gutierrez RM, Ramirez E, Vargas R. Effect of Cirsium pascuarensis on blood glucose levels of normoglycaemic and alloxan-diabetic mice. Phytother Res 2001;15:552-4.

39. Kozycz M, Loli R, Mardarowicz M, Glogniak K, Malm A, Szłapak A. GC/MS analysis of Cirsium maackii and linarin isolated from Cirsium setidens and Aster Scaber in human brain neuroblastoma SK-N-SH cells. Life Sci 2016;148:156-7.

40. Kwon HY, Hoshi N, Saka J, Ohkawa H, Oishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351-8.

41. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:249-54.

42. Nazaraj J. Flavonoid compounds from Cirsium palustre (L.) Scop. Scop. flowers. Biochem Syst Ecol 2009;37:525-7. Available from: http://www.wi.linkinghub.elsevier.com/retrieve/pii/S030505480900091X. [Last accessed on 2017 Apr 05].

43. Kozycz M, Glogniak K, Urin B. Phenolic compounds in the flowering herbs of Cirsium esculentum (Siev.) C. A. Mey. Ann Univ Mariae Curie Skłodowska Sect DDD Pharm 2010;23:113-20.

44. Nolasco S, Bertoni M, Malec L, Cattaneo P. Studies on seeds of Onopordum acanthium L. (Scotch thistle), Caudius acanthoides L (gumless thistle) and Cirsium vulgare (Savi) Ten (bull thistle): Extracted hexane crude oils and defatted seed meals. J Am Soc Agric Chem 1981;75:29-34. Available from: https://www.ncbi.nlm.nih.gov/pubmed/15405. [Last accessed on 2017 Apr 05].

45. Kozycz M, Mardarowicz M, Kochmanska J. Chemical composition and variability of the volatile components from inflorescences of Cirsium species. Nat Prod Res 2015;29:1942-4.

46. Nazaraj J, Wais-Bonkovska A, Bonkovski R. Components and antioxidant activity of fruits of Cirsium palustre and C. rivulare. Chem Nat Comp 2012;48:48-10.

47. Orhan I, Delioman-Orhan D, Özbek E. Antiviral activity and cytotoxicity of the lipophilic extracts of various edible plants and their fatty acids. Food Chem 2009;115:701-6.

48. Strawa J, Wais-Bonkovska A, Leszczynska K, Ściepk M, Nazaraj J. Chemical composition and antioxidant, antibacterial activity of Cirsium rivulare (Jacq) All. roots. Nat Prod Res 2016;30:2730-3. Available from: http://www.tandfonline.com/doi/full/10.1080/14786419.2016.1138302. [Last accessed on 2017 Apr 05].

49. Li L, Sun Z, Shang X, Li J, Wang R, Zhu J. Triterpene compounds from Cirsium setosum. Zhongguo Zhong Yao Za Zhi 2012;37:951-5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22792396. [Last accessed on 2017 Apr 05].

50. Prachayasittikul S, Sarabon P, Cherdtrakulkit R, Rushwarat V, Prachayasittikul V. New bioactive triterpenoids and antimarial activity of Diospyros rubra Lec. EXCLI J 2010;9:1-10. Available from: http://www.excli.de/voll/prachayasittikul_triterpenoids2010/prachayasittikul-proof.pdf. [Last accessed on 2017 May 16].

51. Mathur SB, Gonzalez L. Identification of terpenoids from the leaves of Piptocarpa paradoxia and their biological activities. Nat Prod 1982;45:495-6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15405. [Last accessed on 2017 May 16].

52. Agidew E, Renee MA, Deyou T. Phytochemical investigation of Sapum ellipticum. J Nat Prod Res 2013;3:1-16.

53. Lakshmi V, Mahdi AA, Ahmad MK, Agarwal SK, Srivastava AK. Antidiabetic activity of lupeol triterpenes from C. rivulare in streptozotocin-induced diabetic rats. Bangladesh Pharm J 2015;17:138-46. Available from: http://www.banglapjol.info/index.php/BPJ/article/view/22330. [Last accessed on 2017 May 16].

54. Preetha SR, Kannappa M, Selvakumar E, Nagaraj M, Varalakshmi P. Lupeol ameliorates a flavacin B1-induced pancreatic healing damage in rats. Comp Biochem Physiol C Toxicol Pharmacol 2008;143:333-9.

55. Siddique HR, Saleem M. Beneficial health effects of luteolin trihydroxytrone: A Review of preclinical studies. Life Sci 2011;88:285-93.

56. Ezzat SM, Abdallah HM, Fawzy GA, El-Maraghy SA. Hepatoprotective constituents of Ton lis raeda Moench (Apiaceae). Nat Prod Res 2012;26:282-5.

57. Kunz HD, Kunz E. Hepatology: Principles and Practice. 2nd ed. Germany, Heidelberg: Springer Medizin-Verlag; 2006.

58. Fernández-Martínez E, Wens-Flores I, Moreno MG, Ortiz MJ, Muriel P, Pérez-Alvarez V. Short-term effects of thiolamide analogs on hepatic glycogen and nitric oxide in endotoxin-
challenged rats. Gen Physiol Biophys 2008;27:203-10.

68. Bhandari P, Patel NK, Bhutani KK. Synthesis of new heterocyclic lupeol derivatives as nitric oxide and pro-inflammatory cytokine inhibitors. Bioorg Med Chem Lett 2014;24:3596-9.

69. Khan ME, Maurya CK, Dev K, Arha D, Rai AK, Tamrakar AK, et al. Design and synthesis of lupeol analogues and their glucose uptake stimulatory effect in L6 skeletal muscle cells. Bioorganic Med Chem Lett 2014;24:2674-9.

70. Radziuk J, Pye S. Hepatic glucose uptake, gluconeogenesis and the regulation of glycogen synthesis. Diabetes Metab Res Rev 2001;17:250-72. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11544610. [Last accessed on 2017 May 16].

71. Zhu R, Wang Y, Zhang L, Guo Q. Oxidative stress and liver disease. Hepatol Res 2012;42:341-9.

72. Santori FR. Nuclear hormone receptors put immunity on sterols. Eur J Immunol 2015;45:2730-41. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26222181. [Last accessed on 2017 May 16].